🌿 Viloxazine Novel ADHD Mechanism Simulator

Baseline — Seeking a Non-Stimulant ADHD Option

Patient needs non-stimulant therapy; atomoxetine tolerability issues considered.

• ~20%: Atomoxetine GI intolerance (placeholder reference figure)
• 2: Non-stimulant drug classes (NRI vs. alpha-2 agonist)
• 0%: Baseline NET blockade (pre-treatment state)
• High: ADHD symptom burden (untreated core symptoms)

Why atomoxetine sometimes falls short

GI upset and sedation limit adherence for some patients.

Non-stimulant class overview

NET inhibitors and alpha-2 agonists are the main alternatives.

Setting the stage for viloxazine

A mechanistically distinct NRI option is introduced next.

Viloxazine Blocks the Norepinephrine Transporter

Selective NET inhibition raises synaptic norepinephrine, core shared mechanism.

• High: NET selectivity (minimal DAT/SERT affinity)
• Hours: Onset of NET blockade (after first dose)
• SNRI-like: Mechanism class (selective NE reuptake inhibitor)
• NET block: Shared trait w/ atomoxetine (core overlapping mechanism)

Blocking presynaptic reuptake

Viloxazine occupies NET, slowing norepinephrine clearance from the cleft.

Prefrontal cortex signaling rises

Extracellular norepinephrine accumulates near postsynaptic receptors.

Comparison to atomoxetine

Core NET mechanism resembles atomoxetine's primary action.

A Distinct Serotonergic Receptor Layer

5-HT2B antagonism and 5-HT2C agonism add a second, unshared pathway.

• Antagonist: 5-HT2B action (receptor subtype modulation)
• Agonist: 5-HT2C action (receptor subtype modulation)
• None: Atomoxetine overlap (not shared with atomoxetine)
• Mood-linked: Relevance (serotonergic circuit involvement)

5-HT2B receptor antagonism

Viloxazine dampens 5-HT2B signaling at select receptor sites.

5-HT2C receptor agonism

Partial 5-HT2C activation modulates downstream serotonergic tone.

Why this matters clinically

Adds a mechanism atomoxetine simply does not possess.

Norepinephrine Plus Serotonergic Modulation Together

Dual-pathway engagement supports ADHD control and mood-related benefit.

• Substantial: ADHD symptom improvement (placeholder composite estimate)
• Emerging: Mood co-benefit signal (in some patient subsets)
• 2: Pathways engaged (noradrenergic + serotonergic)
• Weeks: Time to fuller effect (gradual onset curve)

Core ADHD symptom control

Sustained NET blockade drives attention and focus improvement.

Mood and anxiety co-benefit

Serotonergic modulation may ease comorbid mood symptoms.

Dose and duration dependence

Effect size builds with dose and weeks of therapy.

A Mechanistically Distinct Non-Stimulant Alternative

Viloxazine offers an option when atomoxetine underperforms or mood matters.

• Non-stimulant ADHD: Primary use case (adults and pediatric patients)
• Dual pathway: Differentiator (NE + serotonergic modulation)
• Comorbid mood: Best fit scenario (or atomoxetine intolerance)
• Favorable: Overall outcome (placeholder summary indicator)

When to consider viloxazine

Useful if atomoxetine is poorly tolerated by the patient.

Mood-symptom consideration

Comorbid mood or anxiety symptoms may favor this option.

Overall clinical positioning

A distinct, dual-mechanism non-stimulant addition to ADHD care.